143 related articles for article (PubMed ID: 14582448)
1. LXR agonists for the treatment of atherosclerosis.
Jaye M
Curr Opin Investig Drugs; 2003 Sep; 4(9):1053-8. PubMed ID: 14582448
[TBL] [Abstract][Full Text] [Related]
2. Liver X receptors and the control of cholesterol homeostasis: potential therapeutic targets for the treatment of atherosclerosis.
Millatt LJ; Bocher V; Fruchart JC; Staels B
Biochim Biophys Acta; 2003 Mar; 1631(2):107-18. PubMed ID: 12633677
[TBL] [Abstract][Full Text] [Related]
3. Liver X receptors (LXRs). Part I: structure, function, regulation of activity, and role in lipid metabolism.
Wójcicka G; Jamroz-Wiśniewska A; Horoszewicz K; Bełtowski J
Postepy Hig Med Dosw (Online); 2007 Dec; 61():736-59. PubMed ID: 18063918
[TBL] [Abstract][Full Text] [Related]
4. T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice.
Terasaka N; Hiroshima A; Koieyama T; Ubukata N; Morikawa Y; Nakai D; Inaba T
FEBS Lett; 2003 Feb; 536(1-3):6-11. PubMed ID: 12586329
[TBL] [Abstract][Full Text] [Related]
5. Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists.
Levin N; Bischoff ED; Daige CL; Thomas D; Vu CT; Heyman RA; Tangirala RK; Schulman IG
Arterioscler Thromb Vasc Biol; 2005 Jan; 25(1):135-42. PubMed ID: 15539622
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo.
Naik SU; Wang X; Da Silva JS; Jaye M; Macphee CH; Reilly MP; Billheimer JT; Rothblat GH; Rader DJ
Circulation; 2006 Jan; 113(1):90-7. PubMed ID: 16365197
[TBL] [Abstract][Full Text] [Related]
7. Liver x receptor agonists inhibit cytokine-induced osteopontin expression in macrophages through interference with activator protein-1 signaling pathways.
Ogawa D; Stone JF; Takata Y; Blaschke F; Chu VH; Towler DA; Law RE; Hsueh WA; Bruemmer D
Circ Res; 2005 Apr; 96(7):e59-67. PubMed ID: 15790955
[TBL] [Abstract][Full Text] [Related]
8. Liver X receptors (LXR) as therapeutic targets in dyslipidemia.
Bełtowski J
Cardiovasc Ther; 2008; 26(4):297-316. PubMed ID: 19035881
[TBL] [Abstract][Full Text] [Related]
9. Synthetic LXR agonists increase LDL in CETP species.
Groot PH; Pearce NJ; Yates JW; Stocker C; Sauermelch C; Doe CP; Willette RN; Olzinski A; Peters T; d'Epagnier D; Morasco KO; Krawiec JA; Webb CL; Aravindhan K; Jucker B; Burgert M; Ma C; Marino JP; Collins JL; Macphee CH; Thompson SK; Jaye M
J Lipid Res; 2005 Oct; 46(10):2182-91. PubMed ID: 16024916
[TBL] [Abstract][Full Text] [Related]
10. Liver X receptor agonists as potential therapeutic agents for dyslipidemia and atherosclerosis.
Lund EG; Menke JG; Sparrow CP
Arterioscler Thromb Vasc Biol; 2003 Jul; 23(7):1169-77. PubMed ID: 12615685
[TBL] [Abstract][Full Text] [Related]
11. Induction of transglutaminase 2 by a liver X receptor/retinoic acid receptor alpha pathway increases the clearance of apoptotic cells by human macrophages.
Rébé C; Raveneau M; Chevriaux A; Lakomy D; Sberna AL; Costa A; Bessède G; Athias A; Steinmetz E; Lobaccaro JM; Alves G; Menicacci A; Vachenc S; Solary E; Gambert P; Masson D
Circ Res; 2009 Aug; 105(4):393-401. PubMed ID: 19628791
[TBL] [Abstract][Full Text] [Related]
12. Liver X receptor-alpha gene expression is positively regulated by thyroid hormone.
Hashimoto K; Matsumoto S; Yamada M; Satoh T; Mori M
Endocrinology; 2007 Oct; 148(10):4667-75. PubMed ID: 17628006
[TBL] [Abstract][Full Text] [Related]
13. The nuclear receptor LXR is a glucose sensor.
Mitro N; Mak PA; Vargas L; Godio C; Hampton E; Molteni V; Kreusch A; Saez E
Nature; 2007 Jan; 445(7124):219-23. PubMed ID: 17187055
[TBL] [Abstract][Full Text] [Related]
14. Liver X receptor activation potentiates the lipopolysaccharide response in human macrophages.
Fontaine C; Rigamonti E; Nohara A; Gervois P; Teissier E; Fruchart JC; Staels B; Chinetti-Gbaguidi G
Circ Res; 2007 Jul; 101(1):40-9. PubMed ID: 17540978
[TBL] [Abstract][Full Text] [Related]
15. Activation of liver X receptor sensitizes mice to gallbladder cholesterol crystallization.
Uppal H; Zhai Y; Gangopadhyay A; Khadem S; Ren S; Moser JA; Xie W
Hepatology; 2008 Apr; 47(4):1331-42. PubMed ID: 18318438
[TBL] [Abstract][Full Text] [Related]
16. Regulation of the aldo-keto reductase gene akr1b7 by the nuclear oxysterol receptor LXRalpha (liver X receptor-alpha) in the mouse intestine: putative role of LXRs in lipid detoxification processes.
Volle DH; Repa JJ; Mazur A; Cummins CL; Val P; Henry-Berger J; Caira F; Veyssiere G; Mangelsdorf DJ; Lobaccaro JM
Mol Endocrinol; 2004 Apr; 18(4):888-98. PubMed ID: 14739254
[TBL] [Abstract][Full Text] [Related]
17. Liver X receptor modulators: effects on lipid metabolism and potential use in the treatment of atherosclerosis.
Fiévet C; Staels B
Biochem Pharmacol; 2009 Apr; 77(8):1316-27. PubMed ID: 19101522
[TBL] [Abstract][Full Text] [Related]
18. Cholesterol independent effect of LXR agonist TO-901317 on gamma-secretase.
Czech C; Burns MP; Vardanian L; Augustin A; Jacobsen H; Baumann K; Rebeck GW
J Neurochem; 2007 May; 101(4):929-36. PubMed ID: 17472585
[TBL] [Abstract][Full Text] [Related]
19. Identification of macrophage liver X receptors as inhibitors of atherosclerosis.
Tangirala RK; Bischoff ED; Joseph SB; Wagner BL; Walczak R; Laffitte BA; Daige CL; Thomas D; Heyman RA; Mangelsdorf DJ; Wang X; Lusis AJ; Tontonoz P; Schulman IG
Proc Natl Acad Sci U S A; 2002 Sep; 99(18):11896-901. PubMed ID: 12193651
[TBL] [Abstract][Full Text] [Related]
20. Cross-talk between fatty acid and cholesterol metabolism mediated by liver X receptor-alpha.
Tobin KA; Steineger HH; Alberti S; Spydevold O; Auwerx J; Gustafsson JA; Nebb HI
Mol Endocrinol; 2000 May; 14(5):741-52. PubMed ID: 10809236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
